Waalkes T P, Abeloff M D, Ettinger D S, Woo K B, Kuo K C, Gehrke C W
Cancer. 1983 Jul 1;52(1):131-9. doi: 10.1002/1097-0142(19830701)52:1<131::aid-cncr2820520124>3.0.co;2-8.
The levels for serum protein bound neutral carbohydrates (fucose, mannose, and galactose) were determined at specific intervals for 40 patients with small cell carcinoma of the lung and compared to the corresponding carcinoembryonic antigen (CEA) levels. In pretreatment samples, the frequency of elevation was 92.5% for fucose and 77.5% each for mannose and for galactose. CEA determined in these same samples was elevated (greater than 5 ng/ml) in 45.0%. One or more of the three carbohydrate levels were elevated in pretreatment serum of 95.0% of the patients. The individual frequency of elevation for each carbohydrate was significantly related to initial stage of disease (P less than 0.01). Median survival was significantly longer for patients based on a discriminant of less than 3 carbohydrates elevated in pretreatment samples (25 months) to all 3 elevated (11 months) with P = 0.0302. A single value, termed the biomarker index, was calculated to represent the summation of the individual carbohydrate levels per individual serum sample. The biomarker index was found to be directly correlated with extent of primary disease, number of metastic sites, tumor burden, and clinical response categories assessed at serial time points. For patients with both low Biomarker Index values and normal CEA levels in pretreatment samples, an initial rise in both determinations occurred frequently corresponding to partial or complete tumor response. The occurrence of such discordant results must be considered as a likely possibility for those patients with low or normal pretreatment biological marker levels and subsequent response to primary chemotherapy.
在特定时间间隔内,对40例小细胞肺癌患者测定了血清蛋白结合中性碳水化合物(岩藻糖、甘露糖和半乳糖)水平,并与相应的癌胚抗原(CEA)水平进行比较。在预处理样本中,岩藻糖升高的频率为92.5%,甘露糖和半乳糖升高的频率均为77.5%。在这些相同样本中测定的CEA升高(大于5 ng/ml)的比例为45.0%。95.0%的患者预处理血清中三种碳水化合物水平中的一种或多种升高。每种碳水化合物升高的个体频率与疾病的初始阶段显著相关(P<0.01)。根据预处理样本中升高的碳水化合物少于3种(25个月)与3种均升高(11个月)的判别标准,患者的中位生存期有显著差异,P = 0.0302。计算出一个称为生物标志物指数的单一值,以代表每个个体血清样本中单个碳水化合物水平的总和。发现生物标志物指数与原发疾病的范围、转移部位的数量、肿瘤负荷以及在连续时间点评估的临床反应类别直接相关。对于预处理样本中生物标志物指数值低且CEA水平正常的患者,这两种测定的初始升高经常与部分或完全肿瘤反应相对应。对于预处理生物标志物水平低或正常且随后对一线化疗有反应的患者,出现这种不一致结果的可能性必须予以考虑。